Anthem Biosciences IPO Day 1: How Much Rs 3,395 Crore IPO Has Been Subscribed On Monday? Should You Buy?

Anthem Biosciences IPO Day 1: The Bengaluru-based contract research, development, and manufacturing organisation (CRDMO), Anthem Biosciences, is eyeing a stock market debut with an offer for sale (OFS) worth Rs 3,395 crore. The IPO opened for subscription on Monday and has been subscribed by 0.30 times, with decent interest among retail investors and institutional investors.

For those who are planning to invest in the Anthem Biosciences IPO, here are all the details about its latest subscription status, grey market premium (GMP), allotment, brokerage review, etc.

Anthem Biosciences IPO Day 1 Subscription Status

The mainboard IPO has been subscribed by around 0.30 times, according to Chittorgarh website data till 1:15 pm. As per the website, the public issue has been subscribed by 0.33 times in the retail investors category, 0.01 times in the QIB category, 0.61 times in the NII category till Monday.

Anthem Biosciences GMP

The recently opened IPO's GMP stood at Rs 105, as per the data till 12:32 pm. Its price band is likely to stay near Rs 570. The current data indicates a listing price of Rs 675 (cap price + today's GMP), which means that the stock is likely to debut with a gain/loss per share of 18.42%, according to website Investorgain.

Anthem IPO Subscription Opening, Closing Date

The IPO has opened for subscription on Monday, July 14 and will close on Thursday, July 16.

Anthem IPO Size, Price Band

The company's IPO price band has been declared at Rs540 to Rs 570 per equity share. With the IPO launch, the company is aiming to raise an estimated Rs 3,395 crore.

Issue Allotment Date

The issue is likely to see an allotment on July 17 and its listing is likely to occur on July 21. KFin Technologies Ltd has been appointed as the registrar for the process. Whereas, JP Morgan India, JM Financial, Citigroup Global Markets, and Nomura Financial Advisors have been appointed lead managers of the public offer.

Anthem Biosciences IPO: Should You Subscribe Or Not?

Considering Anthem Biosciences stronghold in the industry and its positive outlook, brokerages SBI Securities, and Aditya Birla Capital Stock and Securities have given a favourable rating for the IPO.

Anthem is a leading player in CRDMO services and is supported by strong business model and positive pipeline. "The company is backed by a seasoned leadership team with deep industry expertise which is reflected in its excellent financial performance & best in industry metrices. All these factors considered together command premium valuations over the industry averages. The issue at the upper price band of ₹570 is valued at 71x FY25 P/E as compared to the listed peers average of ~95x. We recommend "Subscribing" to the issue," noted Aditya Birla Capital Securities.

Strong business pipeline, capacity expansion plans, and well established records make it a favourable investment option for long-term gains, according to SBI Securities.

"The company, at the upper price band of Rs 570, is valued at a P/E multiple of 70.9x based on FY25 earnings on post issue capital. The company has registered strong Revenue/EBITDA/Adj.PAT CAGR of 32%/25%/18% (FY23-FY25) to Rs 1,845 cr/ Rs 671 cr/ Rs 451 cr respectively. While comparing with peers, the IPO is fairly priced along with a superior return and margin profile. We recommend investorsto SUBSCRIBE the IPO at Cut-Off price for long term investment horizon," noted SBI Securities.

About Anthem Biosciences

The Bengaluru-based company was established in 2006. It is an innovation-driven and technology focus firm which has a fully integrated capabilities offering end-to-end services for both New Chemical Entities and New Bilogical Entities.

Its top portfolio includes five of the top six commercialised molecules produced for three major pharmaceutral firms.

"We are partners to global innovator firms to help them discover new drugs. It is a new-age business which is different from pharmaceutical business in India which is largely generics based. We do end-to-end partnerships, where we start from discovery of the drug, then channelising its development and then all the way up to its manufacturing. We assist companies and innovators in each step," Ajay Bhardwaj, CEO, Founder and Managing Director, Anthem Biosciences, told CNBC TV18 on Monday.

The company serves multiple biotech and pharma companies and reached a Rs 1,000 crore revenue milestone within 14 years and recorded its highest growth among peers in financial year 2024-25.